Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Instagram Outage Disrupts Thousands of U.S. Users 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
FREDERICK, MD, Dec. 07, 2017 -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced wearable consumer pain management medical device ActiPatch, announced today the launch of their “Try and Tell” program in the United States.
The ActiPatch® Musculoskeletal Pain Therapy is a wearable medical device that is FDA cleared for non-prescription use. There is clinical evidence that in the UK, where a similar opioid crisis is unfolding, ActiPatch users reported:
- Reduced opioid pain medication use by 33%
- Reduced other prescription pain medication use by 65%
- Reduced pain level by 57%
- Reduced side-effects from overall pain medication usage
The “Try and Tell” program drove ActiPatch sales abroad and expect to achieve the same results in the United States. This Wall Street Journal award winning program is meant to help consumers gain experience with the technology with the sampling of the 7-Day ActiPatch Trial device. Which in turn, converts consumers at the rate of 83% to the 30 Day ActiPatch device.
To launch the “Try and Tell” program, we are offering consumers a FREE ActiPatch 7-Day Trial at www.tryActiPatch.com with the promo code TRYANDTELL. Our hope is to expose consumers to an alternative to opioids and other analgesics that is user friendly, without side effects, and actually WORKS!
ActiPatch is also happy to announce retail distribution in the United States through ANDA, as a national distributor. “We are pleased to get ActiPatch national distribution through ANDA to retailers; it is a HUGE win for us here in the United States and will be a catalyst for growth,” said Keith Nalepka, VP of Sales and Marketing at BioElectronics Corp.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy. For more information, please visit www.bielcorp.com .
Paul Knopick 940.262.3584 [email protected]
